Yahoo

Helix BioPharma Corp. Files Clinical Trial Applications for Its Planned European Phase III Efficacy Trial of Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions

AURORA, ON--(Marketwire - December 22, 2011) - Helix BioPharma Corp (TSX: HBP - 新聞) (NYSE Amex: HBP - 新聞) (FRANKFURT: HBP - 新聞), a biopharmaceutical company developing drug candidates for the ...
FierceBiotech

Press Release: Helix BioPharma announces positive phase II clinical results with its Topical Interferon Alpha-2b

Helix BioPharma announces positive phase II clinical results with its Topical Interferon Alpha-2b AURORA, ON, March 30 - Helix BioPharma Corp. Helix today announced positive results from its phase II ...
GEN

FDA Lifts Hold on Start of Helix’ Trial for Topical Treatment for Cervical Lesions

Firm says it will need to find a partner to help shoulder U.S. and European studies with interferon alpha-2b candidate. FDA has lifted a clinical hold preventing Helix BioiPharma from starting a Phase ...
Yahoo

Helix BioPharma Corp. Receives Regulatory Approval to Conduct a European Phase III Clinical Trial of Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions

AURORA, ON--(Marketwire - May 18, 2012) - Helix BioPharma Corp. (TSX:HBP.TO - News) (NYSE Amex:HBP.TO - News) (FRANKFURT:HBP.F - News), a developer of biopharmaceutical drug candidates for the ...